𝔖 Bobbio Scriptorium
✦   LIBER   ✦

7LB Analysis of KRAS mutations in patients with metastatic colorectal cancer receiving panitumumab monotherapy

✍ Scribed by R.G. Amado; M. Wolf; D. Freeman; M. Peeters; E. Van Cutsem; S. Siena; S. Suggs; S. Patterson; D. Chang

Book ID
118624943
Publisher
Elsevier Science
Year
2007
Tongue
English
Weight
38 KB
Volume
5
Category
Article
ISSN
1359-6349

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Panitumumab monotherapy in patients with
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer
✍ J. Randolph Hecht; Amita Patnaik; Jordan Berlin; Alan Venook; Imtiaz Malik; Simo πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 237 KB

## Abstract ## BACKGROUND. The safety and efficacy of the fully human antibody panitumumab was evaluated in patients with metastatic colorectal cancer refractory to available therapies. ## METHODS. This phase 2 open‐label, multicenter study of panitumumab enrolled patients with metastatic colore

Association of K-ras Mutational Status a
Association of K-ras Mutational Status and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Receiving Panitumumab Alone
✍ Daniel J. Freeman; Todd Juan; Maureen Reiner; J. Randolph Hecht; Neal J. Meropol πŸ“‚ Article πŸ“… 2008 πŸ› CIG Media Group, LP. 🌐 English βš– 502 KB

Background: Identifying predictive biomarkers is important to optimally treat patients. This analysis evaluated the association of K-ras, BRAF, and PIK3CA gene mutations with tumor resistance to panitumumab alone. Patients and Methods: From 3 phase II panitumumab metastatic colorectal cancer (mCRC)